Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for c-MAF drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | c-MAF Recombinant Protein (Full-Length / bZIP Domain) High purity (>90%), Endotoxin controlled. Sequence Verified. Suitable for DNA-binding and biophysical assays. |
View c-MAF Products |
| Gene Delivery | c-MAF Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and transcriptional activity assays. |
View c-MAF Products |
| Benchmark Ab | Anti-c-MAF Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and IP validation. |
View c-MAF Products |
| Validator | c-MAF siRNA Set Target-specific knockdown verification in multiple myeloma or T-cell lines. |
View c-MAF Products |
| Related Target A | CCND2 Downstream oncogenic target of c-MAF in multiple myeloma; critical for cell cycle progression. |
View CCND2 Products |
| Related Target B | IL-4 Key Th2 cytokine directly transactivated by c-MAF; essential biomarker for immune regulation assays. |
View IL-4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Transcription factor aggregation and instability during in vitro screening | Optimized buffer formulation preserving native folding of the bZIP DNA-binding domain |
| Selectivity profiling within the MAF family (c-MAF, MAFA, MAFB) | High-purity recombinant homolog panel strictly verified by mass spectrometry |
| Lack of standardized positive controls for cellular translocation | Sequence-verified clinical benchmark and validation-grade antibodies included |
| Off-target effects in phenotypic assays | Sequence-specific siRNA pool included for target knockdown validation |
Live c-MAF/MAF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of c-MAF (cellular musculoaponeurotic fibrosarcoma) is an emerging frontier in both oncology and immunology. As a basic leucine zipper (bZIP) transcription factor, c-MAF acts as a master regulator of Th2 cell differentiation, M2 macrophage polarization, and oncogenic signaling in multiple myeloma (specifically driven by the t(14;16) translocation). Because transcription factors are historically "undruggable," the industry is shifting from traditional small-molecule inhibitors toward innovative modalities such as PROTACs (Proteolysis Targeting Chimeras), molecular glues, and RNA therapeutics to selectively degrade or silence c-MAF.
The next wave of R&D is focused on overcoming drug resistance in multiple myeloma by co-targeting c-MAF downstream effectors (like CCND2 and Integrin beta 7) and modulating the tumor microenvironment via c-MAF-mediated macrophage reprogramming. High-fidelity in vitro and cell-based assays are critical to validating these highly specialized modalities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Degraders | Academic Institutes, Biotech Startups | Multiple Myeloma, Solid Tumors | Degradation kinetics (Need high-purity recombinant c-MAF for ternary complex SPR assays) |
| Small Molecule Inhibitors | Pharmaceutical Corporates | Autoimmune Diseases, Th2-mediated disorders | DNA-binding inhibition (Need functional bZIP domain protein for EMSA/FP assays) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Multiple Myeloma bone metastasis | Target knockdown validation (Need sequence-verified c-MAF Lentivirus for stable overexpressing cells) |